Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 BRL | -3.67% | -22.65% | -56.34% |
Mar. 28 | Transcript : Diagnósticos da América S.A., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 27 | Diagnósticos da América S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-56.34% | 600M | C+ | ||
+14.91% | 82.27B | C+ | ||
+11.06% | 29.43B | C+ | ||
-12.02% | 16.82B | B | ||
-5.56% | 15.89B | A- | ||
-7.91% | 14.1B | A- | ||
-0.10% | 12.05B | A- | ||
-30.35% | 12.01B | - | - | |
+21.84% | 11.19B | B- | ||
-6.38% | 11.09B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DASA3 Stock
- Ratings Diagnosticos da América S.A.